Find Out If You Have a Case
Free, confidential review by Attorney Matthew T. Marin. Prefer to talk? Call (888) 348-2735.
Dupixent Lawsuit — Free, Confidential Case Review
Dupixent lawsuit help for Massachusetts patients
Marin & Murphy is licensed in Massachusetts. Two confidential minutes tells you whether you have a case.
ACTIVE LITIGATION — NO SETTLEMENT. MDL 3180 underway · filing deadlines vary by state.
Were you — or someone you love — diagnosed with CTCL or another T-cell lymphoma after taking Dupixent?
Check if my case qualifiesfree · confidential · takes 2 minutes
I’m not sure of my exact diagnosis →
No documents needed · confidential · an answer either way · no fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.
Or talk to a person now: (888) 348-2735 — answered 24/7
Stefanie A. Murphy & Matthew T. Marin
Partners
Every Dupixent inquiry gets a personal review — and an honest answer either way, free and without obligation.
Claims are brought against Sanofi and Regeneron, the makers of Dupixent — not against your doctor. Conversations are confidential. Some matters may be referred to other lawyers. No settlement has been reached, and most cases are in their earliest stages; every case must be proven on its own facts. Attorney Advertising.
Marin & Murphy Law Firm is currently accepting Dupixent CTCL cases from Massachusetts residents. The core criterion is a diagnosis of cutaneous T-cell lymphoma (CTCL) or a qualifying T-cell lymphoma subtype made during or after Dupixent (dupilumab) use — there is no minimum length of use, and families may bring a claim through the estate of a loved one who has died. A Massachusetts case becomes part of the federal consolidation in MDL 3180 in the District of New Jersey.
This page is about a lawsuit — it is not medical advice, and filing a claim does not require you to stop taking Dupixent. Decisions about your medication belong with you and your doctor.
Lawsuits consolidated in MDL 3180 (D.N.J.) allege that Dupixent (dupilumab) is associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and that the manufacturers failed to warn about it. No court has ruled on these allegations, no settlement exists, and the litigation is in its earliest stages. Published studies report a statistical association — which the study authors themselves note does not establish causation — and the FDA has identified a potential safety signal it is still evaluating; Dupixent’s FDA label does not currently warn about lymphoma. Whether any individual has a claim depends on their medical records and the law of their state.
Is Marin & Murphy Accepting Dupixent CTCL Cases From Massachusetts?
Yes. Both of the firm’s attorneys, Matthew T. Marin and Stefanie A. Murphy, are admitted to practice in Massachusetts. The Dupixent lawsuit is not a class action but a set of individual claims consolidated for pretrial proceedings as MDL 3180, and a Massachusetts resident’s claim is evaluated on its own records: the pathology report establishing the diagnosis, the pharmacy and treatment history establishing Dupixent use, and the dates connecting the two. Whether a claim is accepted is determined after review, and no attorney-client relationship is created until a written engagement agreement is signed.
Who Qualifies From Massachusetts?
The criteria are national, not state-specific — the full detail, including all fourteen qualifying T-cell lymphoma subtypes, is set out on the who qualifies page. In short:
Dupixent Lawsuit Qualification Checklist
- You took Dupixent (dupilumab) — for any length of time; there is no minimum duration of use
- You were diagnosed with cutaneous T-cell lymphoma (CTCL) or a qualifying T-cell lymphoma subtype during or after your Dupixent use
- Claims may be brought for a family member who has died, through their estate
- You are not currently represented by another attorney or law firm for this claim
Free Confidential Evaluation — No Fee Unless There Is a Recovery
Call (888) 348-2735 or use the confidential case review form on this page.
Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.
A Massachusetts Resident’s Dupixent Case in MDL 3180
A Massachusetts resident filed Zaikis v. Regeneron Pharmaceuticals, Inc. directly in the District of New Jersey in July 2026 (No. 3:26-cv-08509, public docket), alleging that Dupixent was prescribed in about October 2022 and that he was later diagnosed with mycosis fungoides; the complaint names Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC and is consolidated in MDL 3180. These are allegations from a complaint; no court has ruled on them, and no settlement exists. Marin & Murphy Law Firm is licensed in Massachusetts and reviews Dupixent CTCL claims from Massachusetts residents directly; the criteria are described on do I qualify.
Where Would a Massachusetts Dupixent Case Be Filed?
Massachusetts has one federal district court: the United States District Court for the District of Massachusetts. A Dupixent CTCL suit filed there does not stand alone: through the Judicial Panel on Multidistrict Litigation, these cases are centralized as MDL 3180 before Judge Zahid N. Quraishi in the United States District Court for the District of New Jersey, so a Massachusetts case is transferred to the MDL for coordinated pretrial proceedings — or, where the MDL court’s case-management orders permit, filed in the District of New Jersey directly. Either route leads to the same consolidated proceeding, and your case remains an individual claim; an MDL is not a class action.
What Is the Filing Deadline for a Massachusetts Dupixent Claim?
Massachusetts’s general statute of limitations for personal-injury claims is three years under Mass. Gen. Laws ch. 260, §§ 2A, 4. Massachusetts applies a discovery rule: accrual occurs when the plaintiff discovers, or reasonably should have discovered, that she has been harmed by the defendant’s conduct. None of that is a calculation to run on your own: accrual dates, the discovery doctrine, and the theory pleaded can each move the deadline, and reviewing those dates against your records is part of the free evaluation.
A wrongful-death claim carries a three-year period that begins at death (Mass. Gen. Laws ch. 229, § 2), brought by the personal representative.
How Common Is CTCL in Massachusetts?
Massachusetts is home to about 7.1 million people (U.S. Census Bureau, 2024 estimate). Cutaneous T-cell lymphoma is rare — roughly 8.55 new cases per million person-years (SEER) — which works out to on the order of 60 new CTCL diagnoses across Massachusetts in a typical year. That rarity is exactly why a diagnosis deserves an individual look: statistics do not decide any single claim, and your medical records are what a review actually reads.
Free Confidential Evaluation — No Fee Unless There Is a Recovery
Call (888) 348-2735 or use the confidential case review form on this page.
Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.
Prefer to start online? The free case review takes about two minutes and asks only what the criteria turn on: your diagnosis, your Dupixent use, and their timing.
Massachusetts Dupixent Lawsuit FAQs
Is Marin & Murphy accepting Dupixent CTCL cases from Massachusetts?
Yes. Marin & Murphy Law Firm is currently accepting Dupixent CTCL cases from Massachusetts residents. The evaluation is free and confidential, and no attorney-client relationship is created until a written engagement agreement is signed.
Who qualifies to file from Massachusetts?
The criteria are the same nationally: a diagnosis of cutaneous T-cell lymphoma or a qualifying T-cell lymphoma subtype during or after Dupixent use, with no minimum duration of use. Claims may also be brought through the estate of a family member who has died.
Where would a Massachusetts Dupixent case actually be filed?
Massachusetts’s federal court is the United States District Court for the District of Massachusetts. Federal Dupixent CTCL cases are centralized in MDL 3180 in the District of New Jersey, so a Massachusetts case is transferred there — or filed there directly where permitted — for coordinated pretrial proceedings, and it remains an individual claim throughout.
What is the deadline to file a Massachusetts Dupixent claim?
Deadlines come from Massachusetts statutes of limitation and related doctrine — the section above covers the framework. How it applies depends on the dates in your records, and reviewing them is part of the free evaluation.
What does it cost to bring a claim?
Representation is on a contingency basis: no fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery; you are not responsible for them if there is no recovery, unless a court directs otherwise.
Has a court ruled that Dupixent causes CTCL? Is there a settlement?
No and no. Plaintiffs allege an association; published studies report a statistical association their authors note does not establish causation; the FDA is still evaluating a potential signal; and no settlement exists.
Do I have to stop taking Dupixent to file?
No. Filing a claim does not require you to stop taking Dupixent. Decisions about your medication belong with you and your doctor; this is a lawsuit question, not a medical one.
What is MDL 3180?
MDL 3180 is the federal multidistrict litigation consolidating Dupixent CTCL lawsuits for pretrial proceedings in the United States District Court for the District of New Jersey, before Judge Zahid N. Quraishi. Cases are coordinated for efficiency but remain individual claims — an MDL is not a class action.
Nearby states
How Common Is Dupixent in Massachusetts? The Public Numbers
Atopic dermatitis and other inflammatory conditions make Dupixent (dupilumab) a frequently prescribed medication in Massachusetts. Federal drug-utilization data shows how often it is dispensed:
Between 2024 and 2025, Medicaid prescriptions reported in Massachusetts increased around 14%. These counts reflect Medicaid outpatient reporting alone; prescriptions covered by Medicare or private insurance are not included, so the true number of residents of Massachusetts using Dupixent is larger. A small number of privacy-suppressed records are excluded from the totals.
Sources: Centers for Medicare & Medicaid Services, State Drug Utilization Data 2024 and 2025 (accessed August 21, 2026); In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180, JPML Transfer Order, Schedule A (June 4, 2026). Utilization data reflects prescriptions reported by state Medicaid programs and is not evidence that any individual prescription caused injury.
Sources
- U.S. Judicial Panel on Multidistrict Litigation, Pending MDL Dockets by MDL Number (August 3, 2026) — jpml.uscourts.gov
- MDL 3180 docket records — CourtListener dockets 72288297 (JPML) and 73443394 (D.N.J. 3:26-md-03180), reviewed September 15, 2026.
- Mass. Gen. Laws ch. 260, §§ 2A, 4 — Massachusetts statute of limitations discussed above.
- U.S. Census Bureau, Vintage 2024 Population Estimates (NST-EST2024), resident population as of July 1, 2024.
- SEER program data: cutaneous T-cell lymphoma incidence ≈8.55 cases per million person-years.
Attorney admissions: Matthew T. Marin — RI, CT, MA, SC, U.S.D.C. D.R.I. · Stefanie A. Murphy — RI, CT, MA, U.S.D.C. D.R.I./D.Conn./D.Mass.
Attorney Advertising.
Attorney Advertising. This page is for general information and is not legal advice; reading it does not create an attorney-client relationship, and no attorney-client relationship is formed until a written engagement agreement is signed. Marin & Murphy Law Firm attorneys are licensed in Rhode Island, Connecticut, Massachusetts, and South Carolina; the firm’s mass-tort practice is directed from its Charleston, South Carolina office. Responsible attorney: Matthew T. Marin, 997 Morrison Drive, Suite 200, Charleston, SC 29403. Cases may be handled together with co-counsel; whether a claim is accepted is determined after review. No representation is made that the quality of legal services is greater than that of other lawyers. Prior results do not guarantee a similar outcome; every case depends on its own facts.